Ampyra and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Ampyra (dalfampridine), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Tysabri, and have Gait disturbance.

The phase IV clinical study analyzes which people have Hearing loss when taking Ampyra. It is created by eHealthMe based on reports of 76,998 people who have side effects when taking Ampyra from the FDA, and is updated regularly.

What is Ampyra?

Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 77,145 Ampyra users. Check the latest studies of Ampyra.

What is Hearing loss?

Hearing loss is found to be associated with 1,358 drugs and 2,385 conditions by eHealthMe. Check the latest studies of Hearing loss.

On Aug, 11, 2026

76,998 people reported to have side effects when taking Ampyra.
Among them, 53 people (0.07%) have Hearing loss.

Among these 53 people:

How long have people been on Ampyra when they have Hearing loss? *

What is the gender of people who have Hearing loss when taking Ampyra? *

female: 67.92 %
male: 32.08 %

What is the age of people who have Hearing loss when taking Ampyra? *

What are other drugs people take besides Ampyra? *

What are other side effects people have besides Hearing loss? *

Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 17 people, 32.08%
Tinnitus (a ringing in the ears): 16 people, 30.19%
Weakness: 15 people, 28.30%
Dizziness: 11 people, 20.75%
Memory Loss: 11 people, 20.75%
Urinary Tract Infection: 11 people, 20.75%
Fatigue (feeling of tiredness): 11 people, 20.75%
Gait Disturbance: 11 people, 20.75%
Stress And Anxiety: 11 people, 20.75%
Hypoaesthesia (reduced sense of touch or sensation): 10 people, 18.87%

What are the existing conditions these people have? *

Gait Disturbance: 20 people, 37.74%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 3 people, 5.66%
Movement - Uncoordinated: 3 people, 5.66%
Menopause (end of monthly cycles in women): 2 people, 3.77%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 3.77%
Depression: 2 people, 3.77%
Dizziness: 2 people, 3.77%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 2 people, 3.77%
Joint Pain: 2 people, 3.77%
Fatigue (feeling of tiredness): 1 person, 1.89%

* Approximation only. Some reports may have incomplete information.

Do you take Ampyra and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ampyra:

Ampyra (77,145 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Ampyra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,358 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,385 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.